Meriscreen HIV 1-2 WB Rapid Test Kit

Meriscreen HIV 1-2 WB (Advanced Immunochromatographic Diagnostic Detection Matrix)

Meriscreen HIV 1-2 WB Rapid Test Kit is a high-potency, sterile in-vitro diagnostic intervention engineered for the qualitative detection and clean differentiation of antibodies (IgG, IgM, and IgA) specific to Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2) across human serum, plasma, or whole blood landscapes. Utilizing an advanced membrane-bound immunochromatographic sequence, this diagnostic assembly works by concurrently modulating the organized binding of targeted viral antibodies to immobilized recombinant envelope antigens (including specific gp41, gp120 structures for HIV-1 and gp36 matrices for HIV-2) and executing direct colloidal gold or fluorescent-labeled visualization across the testing spectrum. By neutralizing the structural limitations of historical fluid assessments—specifically those compromised by matrix interference, delayed diagnostic timelines, or complex laboratory hardware configurations—and facilitating the organized stabilization of the screening landscape through a high-purity molecular binding complex, Meriscreen effectively promotes a significant optimization of point-of-care diagnostic precision and a reduction in systemic screening verification fatigue. This targeted screening action provides a decisive therapeutic and diagnostic baseline by reinforcing the absolute uniformity of early epidemiological monitoring while promoting a stable, physiological framework for clinical validation and downstream intervention pathways.

Key Features

• Engineered with distinct, high-purity recombinant proteins to deliver clear, visible differentiation between HIV-1 and HIV-2 antibody complexes.
• Clinically recognized for its fluid capillary action that facilitates the natural optimization of rapid reading parameters, yielding diagnostic readouts within 15 to 20 minutes.
• Specifically optimized to detect early-stage immunoglobulins, ensuring a robust defense against localized false-negative assessments during critical screening windows.
• Acts as a functional operational catalyst to validate testing integrity via a built-in control line (C), documenting proper fluid migration and active reagent performance.
• Requires micro-volume specimen inputs, making the unit tailored to handle diverse clinical configurations without requiring high-volume vascular depletions.

Key Kit Components

• Targeted Immunochromatographic Test Cassettes
• Aseptically Calibrated Running Buffer
• Micro-Capillary Fluid Pipettes

How to Use

• The diagnostic evaluation must be conducted under clean parameters. Ensure all kit elements, running buffers, and patient specimens are equilibrated to ambient room temperature prior to executing the extraction sequence.
• Obtain a precise micro-volume aliquot of whole blood via standard finger-prick or venipuncture matrices, or utilize prepared clear serum/plasma test layers.
• Utilize the provided capillary pipette to transfer the specified volume of specimen into the designated sample well (S) interface of the diagnostic cassette.
• Introduce the calibrated drop sequence of the provided running buffer solution immediately into the sample or buffer well to activate the lateral flow capillary migration sequence.
• Allow the matrix to remain completely undisturbed; document and read the visible line development precisely between 15 and 20 minutes post-activation. Do not interpret structural changes after 30 minutes.
• Verify the presence of the control line (C) to confirm kit validity; the appearance of distinct lines in the test zones (1 and/or 2) indicates a reactive diagnostic sequence requiring formal confirmation.

Precautions

• This is a targeted rapid screening intervention. All reactive or indeterminate readouts must be discussed with a specialist and subjected to a formal diagnostic Western Blot or molecular PCR confirmation protocol.
• Each test cassette is engineered for strict single-use application; do not re-use individual matrix units or inter-mix components across differing manufacturing batch configurations.
• Avoid introducing external environmental moisture or letting unsterile items touch the active sample well window to maintain the structural uniformity of localized diagnostic lines.
• Handle all biological specimens as potentially infectious agents; execute standard universal healthcare isolation practices and follow formal clinical disposal steps post-evaluation.
• Keep the diagnostic kits stored in a cool, dry environment (between 2°C and 30°C). Do not expose the active test strips to freezing temperatures or direct thermal sources before use.

Warning

• Strictly engineered for external laboratory screening sequences; do not utilize for internal consumption, direct dermal exposure, or parental injection pathways.
• Do not deploy the diagnostic components beyond the documented manufacturer expiration parameters, as molecular degradation can cause invalid or inaccurate results.
• Do not utilize the individual test cassette if the protective foil pouch matrix is found compromised or the included desiccant shows signs of humidity saturation prior to opening.
• Do not dilute the running buffer matrix with external tap water or saline variants to preserve the calibrated ionic balance required for correct antibody capture.

Legal Disclaimer: Meriscreen HIV 1-2 WB Rapid Test Kit is a specialized in-vitro screening tool. Individual diagnostic outcomes and line intensities vary based on the patient’s biological antibody titers and the timeline of viral exposure. This product is for use under professional clinical guidance only. This information is for educational purposes and is not a substitute for formal professional medical consultation.